[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343296-105":59,"doc-detail-343296-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","tuba1c-orchestrates-the-immunosuppressive-tumor-microenvironment-and-resistance-to-immune-checkpoint-blockade-in-clear-cell-renal-cell-carcinoma","TUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma","","Clear cell renal cell carcinoma (ccRCC) remains difficult to treat, particularly in advanced disease where immune checkpoint blockade (ICB) responses vary. Elevated TUBA1C is linked to poor outcomes in multiple cancers, yet its function in ccRCC and its impact on ICB resistance are unclear. Single-cell and pan-cancer analyses, pathway modeling, and validation in clinical cohorts identify TUBA1C-driven immunosuppression and worse prognosis via PI3K/AKT signaling and immune cell infiltration, supporting TUBA1C as a biomarker and therapeutic target to improve ICB responsiveness.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tuba1c-orchestrates-the-immunosuppressive-tumor-microenvironment-and-resistance-to-immune-checkpoint-blockade-in-clear-cell-renal-cell-carcinoma/343296/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tuba1c-orchestrates-the-immunosuppressive-tumor-microenvironment-and-resistance-to-immune-checkpoint-blockade-in-clear-cell-renal-cell-carcinoma/343296.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study address in clear cell renal cell carcinoma (ccRCC)?","Question",{"text":113,"@type":114},"The study targets treatment challenges in advanced ccRCC, where immune checkpoint blockade (ICB) efficacy varies and resistance can develop.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How is TUBA1C related to ICB resistance according to the results?",{"text":118,"@type":114},"TUBA1C expression is higher in malignant cells after ICB therapy and correlates with ICB resistance in ccRCC.",{"name":120,"@type":111,"acceptedAnswer":121},"What biological mechanism links high TUBA1C to an immunosuppressive tumor microenvironment?",{"text":122,"@type":114},"High TUBA1C activates the PI3K/AKT pathway and is associated with increased infiltration of regulatory T cells and myeloid-derived suppressor cells.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},343296,1790184070,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Original Research PUBLISHED 05 September 2024 DOI 10.3389/fimmu.2024.1457691  \nOPEN ACCESS  \nEDITED BY Gang Tian,  \nSichuan Province Engineering Technology Research Center of Molecular Diagnosis of Clinical Diseases, China  \nREVIEWED BY Meng Jia,  \nUniversity of Pennsylvania, United States Lihong Pang,  \nGuangxi Medical University, China  \n*CORRESPONDENCE Qingfei Cao  \n [caoqingfei@jzmu.edu.cn](caoqingfei@jzmu.edu.cn)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 01 July 2024  \nACCEPTED 20 August 2024  \nPUBLISHED 05 September 2024  \nCITATION  \nLi J, Chen M, Tong M and Cao Q (2024) TUBA1C orchestrates the immunosuppressive  \ntumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma.  \nFront. Immunol. 15:1457691 .  \ndoi: 10.3389/fimmu.2024.1457691  \nCOPYRIGHT  \n© 2024 Li, Chen, Tong and Cao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma  \nJunyi Li 1,2†, Meixue Chen 2,3†, Ming Tong 1 and Qingfei Cao 1*  \n1 Department of Urology, The First Afﬁliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China, 2The First Clinical Medical College, Jinzhou Medical University, Jinzhou,  \nLiaoning, China, 3 Department of Pediatric, The First Afﬁliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China  \nBackground: Clear cell renal cell carcinoma (ccRCC) poses substantial treatment challenges, especially in advanced stages where the efﬁcacy of immune checkpoint blockade (ICB) therapy varies signiﬁcantly. Elevated expression of the oncogene TUBA1C has been correlated with poor prognosis in various cancers, however, its role in ccRCC is unclear, especially concerning ICB resistance.  \nMethods: Single-cell analysis was used to examine gene expression variations in malignant cells post-ICB therapy. This included investigating TUBA1C expression across different ICB response groups and its relationship with CD274 . A general module of action was identiﬁed through pan-cancer and pan-tissue analysis. TUBA1C expression and its association with clinical characteristics and prognosis was further validated. Multiple algorithms were employed to explore immune cell inﬁltration levels, and the DepMap database was utilized to assess gene dependency and mutation status in kidney cancer cell lines. The in silico knockout of TUBA1C was performed using deep learning model, complemented by immunohistochemical assays, clinical cohort and functional assays validations.  \nResults: TUBA1C expression is elevated in malignant cells following ICB therapy and is correlated with ICB resistance in ccRCC. High TUBA1C expression activates PI3K/AKT pathway and is associated with increased inﬁltration of regulatory T cells and myeloid-derived suppressor cells, which contributes to an immunosuppressive microenvironment in ccRCC. Patients with high TUBA1C expression exhibit a greater tumor mutation burden and increased genetic variation, which causes a worse prognosis. Additionally, TUBA1C dependency and its effects were evident in kidney cancer cell lines, where mutations conferred resistance to anti-PD-L1 therapy. In silico knockout analyses indicated that treatment targeting TUBA1C shifted malignant cells to a state responsive to ICB therapy. Immunohistochemistry, RT-qPCR and clinical cohort validation further conﬁrmed that TUBA1C expression was upregulated and  \nFrontiers in Immunology 01 [frontiersin.org](frontier","cbCaib2H0NVrv7FD","https://ap.wps.com/l/cbCaib2H0NVrv7FD","pdf",33363322,22,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Key topics\n## TUBA1C in ccRCC after ICB\n## PI3K/AKT and immunosuppressive microenvironment\n## Prognostic value and therapeutic targeting","[{\"question\":\"What problem does the study address in clear cell renal cell carcinoma (ccRCC)?\",\"answer\":\"The study targets treatment challenges in advanced ccRCC, where immune checkpoint blockade (ICB) efficacy varies and resistance can develop.\"},{\"question\":\"How is TUBA1C related to ICB resistance according to the results?\",\"answer\":\"TUBA1C expression is higher in malignant cells after ICB therapy and correlates with ICB resistance in ccRCC.\"},{\"question\":\"What biological mechanism links high TUBA1C to an immunosuppressive tumor microenvironment?\",\"answer\":\"High TUBA1C activates the PI3K/AKT pathway and is associated with increased infiltration of regulatory T cells and myeloid-derived suppressor cells.\"}]","TUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma | PDF",1790050650,55,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/470b2acd09bcd8c430216e45857e8ba9.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/056735dc3caff46a04465aa7829f725a.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b979e3e18b752ba0921f20463d5f5ad8.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69ace977d52e3360664f2075135e8f21.webp",980,1385]